Navigation Links
Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
Date:4/2/2008

-Milestone triggers $28.3 million second-tranche investment-

CAMBRIDGE, Mass., April 2, 2008 /PRNewswire/ -- Radius Health ("Radius") announced today the completion of patient enrollment into its Phase II clinical trial of BA058, the company's bone anabolic candidate for treatment of osteoporosis. The Phase II dose-finding study is designed to further evaluate the ability of BA058 to build new bone for the treatment of osteoporosis in postmenopausal women. Radius also announced today the receipt of a second-tranche financing of $28.3 million based on achieving this milestone, for a total second institutional investment of $67.5 million. Six existing venture investors-MPM Capital, The Wellcome Trust, HealthCare Ventures, Oxford Bioscience Partners, BB Biotech Ventures, and Scottish Widows Investment Partnership-participated in the latest closing. Radius will use the funds to support development of the company's four major product candidates.

The randomized, double-blind, placebo- and comparator-controlled Phase II study is evaluating BA058 in 244 otherwise healthy postmenopausal women with osteoporosis at 35 centers in the United States, United Kingdom, Argentina, and India. The trial is designed to evaluate the safety of BA058 across a range of doses as well as its ability to induce bone formation without inducing resorption through measurement of bone formation and resorption markers and by measuring bone mineral density using a number of different modalities. Radius expects to report the results of the Phase II clinical trial by the end of 2008.

"The completion of patient recruitment in this Phase II trial is a very significant achievement for Radius, and we are grateful for the enthusiasm of our investigators, who have worked diligently to exceed our enrollment target for this study," said C. Richard Lyttle, PhD, President and CEO of Radius. "We believe that BA058 represents a next-generation bone anabolic treatment for osteoporosis that promises to build bone more rapidly and to be more convenient for patients to use. We look forward to communicating the results later this year."

About BA058

PTHrP (parathyroid hormone-related protein) is a critical peptide for promoting new bone formation, with a role distinct from PTH (parathyroid hormone), which regulates calcium homeostasis and bone resorption. BA058 is an analog of hPTHrP that is designed to build bone without inducing hypercalcemia or significant resorption. In preclinical testing, BA058 demonstrated the potential to widen the anabolic window for bone therapeutics: i.e., stimulating bone formation with a limited effect on bone resorption. In Phase I studies, BA058 generally was well tolerated and did not induce hypercalcemia in doses up to 80 mcg.

About Osteoporosis

Osteoporosis is a leading cause of morbidity and mortality in elderly people worldwide. In the U.S. alone, more than 44 million men and women have osteoporosis or low bone-mineral density. A 50-year-old woman in the U.S. has a 40 percent lifetime risk of osteoporotic fracture. Twenty percent of hip- fracture patients enter long-term care, and half of this group never returns to living independently.

About Radius (http://www.radiuspharm.com)

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. Radius has raised $91.5 million in private equity financing since its establishment in 2003 and is based in Cambridge, Massachusetts.

Contact:

Nick Harvey

Chief Financial Officer

(617) 551-4704


'/>"/>
SOURCE Radius
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
3. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
4. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
5. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
6. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
7. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
10. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
11. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017  Sanderling Ventures, portfolio company, Torax ... division of Johnson & Johnson. Torax manufactures and markets ... of gastro-esophageal reflux disease (GERD). The LINK device ... and the procedure is currently available in the ... Medical was founded by Sanderling Ventures, Mayo Medical ...
(Date:3/27/2017)... March 27, 2017 BioLineRx Ltd. (NASDAQ/TASE: ... announced today that AGI-134, an immunotherapy for the treatment of ... Ltd., will be featured at the upcoming American Association ... Washington, DC to be held on April 1-5, ... ...
(Date:3/27/2017)... FRANCISCO , March 27, 2017 ... expected to reach USD 16.0 billion by 2025, according ... The growing prevalence of chronic diseases is anticipated to ... chemistry analyzers, which thereby widens the scope for growth ... geriatric and bariatric population, which is highly susceptible to ...
Breaking Medicine Technology:
(Date:3/27/2017)... PA and London UK (PRWEB) , ... March ... ... the speed, agility and ability to gain site attention and engagement over the ... DrugDev educational webinar will discuss how partnering with the right ...
(Date:3/27/2017)... ... March 27, 2017 , ... A study by the founder of ... colleague, Sudeep Roy, MD, was recently published in the American Journal of Cosmetic ... details Drs. Buckingham and Roy’s study on the use of Electro Lube during the ...
(Date:3/27/2017)... Arizona (PRWEB) , ... March 27, 2017 , ... Buzzies ... the top 10 for Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will ... York on April 8. , Project Entrepreneur’s second annual venture competition ignites bold ...
(Date:3/27/2017)... IL (PRWEB) , ... March 27, 2017 , ... ... systems, recently received the CE Certificate of Conformity for the Smart System® 20/20. ... or exceed the highest industry standards and specifications such as ANSI, ISO and ...
(Date:3/27/2017)... ... March 27, 2017 , ... American ... conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a ... with the April edition of American Veterinarian™. , “We look forward ...
Breaking Medicine News(10 mins):